About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the ...

Kimberly-Clark Corporation (NYSE: KMB) today announced that Joseph Romanelli, president of Human Health International for Merck & Co., Inc., Rahway, NJ, USA, ("MSD") has been elected to its board of ...

This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

Detailed price information for Prelude Therapeutics Inc (PRLD-Q) from The Globe and Mail including charting and trades.

Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end. Encouraging clinical responses observed in ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...

Placed second of five finalists for Merck KGaA's EMEA Advance Biotech ... About Theriva Biologics, Inc. Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing ...

Kimberly-Clark Corporation today announced that Joseph Romanelli, president of Human Health International for Merck & Co., Inc., Rahway, NJ, USA, ("MSD") has been elected to its board of directors, ...

In 2024, we established a license and research collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to identify novel targets for inflammatory diseases. In 2021, we entered into ...